Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD)

NCT00831415

Last updated date
Study Location
Pfizer Investigational Site
Aichi, , , Japan
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Major Depressive Disorder
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Outpatients who have completed double-blind therapy in short-term study for the indication of major depressive disorder (MDD), including scheduled evaluations, with no major protocol violations and no study events that, in the opinion of the investigator, would preclude the subject's entry into the long-term, open-label study.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Clinically important abnormalities on baseline (day 56 of the short-term study)
physical examination, or any unresolved clinically significant abnormalities on
electrocardiogram (ECG), laboratory test results, or vital signs recorded before day
56 in the previous short-term study for the indication of MDD.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Major Depressive DisorderA Comparison of Sertraline Versus Venlafaxine XR in the Treatment of Major Depression
NCT00644982
  1. Cairns, Queensland
  2. Everton Park, Queensland
  3. North Cairns, Queensland
  4. Box Hill, Victoria
  5. Heidelberg, Victoria
  6. West Heidelberg, Victoria
  7. West Perth, Western Australia
  8. Adana,
  9. Ankara,
  10. Diyarbakir,
  11. Istanbul,
  12. Izmir,
  13. Izmit,
  14. Malatya,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Major Depressive DisorderStudy Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder
NCT00384033
  1. Beverly Hills, California
  2. Burbank, California
  3. Encino, California
  4. Los Alamitos, California
  5. Newport Beach, California
  6. Northridge, California
  7. Orange, California
  8. Pasadena, California
  9. Upland, California
  10. South Miami, Florida
  11. St. Petersburg, Florida
  12. Edwardsville, Illinois
  13. Farmington Hills, Michigan
  14. Flint, Michigan
  15. Okemos, Michigan
  16. Clementon, New Jersey
  17. Dayton, Ohio
  18. Portland, Oregon
  19. Philadelphia, Pennsylvania
  20. Salt Lake City, Utah
  21. Seattle, Washington
  22. Brown Deer, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Major Depressive DisorderRelapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
NCT00887224
  1. Beverly Hills, California
  2. Encino, California
  3. Los Alamitos, California
  4. Orange, California
  5. Upland, California
  6. Aurora, Colorado
  7. Jacksonville, Florida
  8. South Miami, Florida
  9. St. Petersburg, Florida
  10. St. Petersburg, Florida
  11. Atlanta, Georgia
  12. Smyrna, Georgia
  13. Hoffman Estates, Illinois
  14. Rockville, Maryland
  15. New York, New York
  16. New York, New York
  17. Rochester, New York
  18. Dayton, Ohio
  19. Portland, Oregon
  20. San Antonio, Texas
  21. Seattle, Washington
  22. Edmonton, Alberta
  23. Medicine Hat, Alberta
  24. Kelowna, British Columbia
  25. Vancouver, British Columbia
  26. Bathurst, New Brunswick
  27. Burlington, Ontario
  28. Ottawa, Ontario
  29. Toronto, Ontario
  30. Gatineau, Quebec
  31. Pointe-Claire, Quebec
  32. Sherbrooke, Quebec
  33. Santiago,
  34. Santiago,
  35. Santiago,
  36. Medellin, Antioquia
  37. Barranquilla, Atlantico
  38. Bogota, Cundinamarca
  39. Bucamaranga, Santander
  40. Rijeka,
  41. Zagreb,
  42. Tallinn,
  43. Tallinn,
  44. Tartu,
  45. Voru,
  46. Vöru,
  47. Espoo,
  48. Helsinki,
  49. Joensuu,
  50. Kuopio,
  51. Seinajoki,
  52. Tampere,
  53. Turku,
  54. Caen,
  55. Dole,
  56. Douai,
  57. Orvault,
  58. Rennes,
  59. Liepaja,
  60. Sigulda,
  61. Sigulda,
  62. Strenci,
  63. Kaunas,
  64. Kaunas,
  65. Vilius,
  66. Vilnius,
  67. Vilnius,
  68. Vilnius,
  69. Skorzewo, Poznan
  70. Szczecin,
  71. Torun,
  72. Tuszyn,
  73. Wroclaw,
  74. Zuromin,
  75. Craiova, Dolj
  76. Brasov,
  77. Bucharest,
  78. Bucuresti,
  79. Bucuresti,
  80. Cluj Napoca,
  81. Bojnice,
  82. Bratislava,
  83. Liptovsky Mikulas,
  84. Michalovce,
  85. Rimavska Sobota,
  86. Trencin,
  87. Cape Town, Western Cape
  88. Durban,
  89. Paarl,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Major Depressive DisorderStudy Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)
NCT01056289
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD)
Official Title  ICMJE A 10-Month Open-Label Evaluation Of The Long-Term Safety Of Desvenlafaxine Succinate Sustained Release In Japanese Adults With Major Depressive Disorder
Brief Summary

The primary objective of this study is to evaluate the long-term safety of desvenlafaxine succinate sustained release tablets during 10-month open-label treatment of Japanese subjects with major depressive disorder (MDD).

The secondary objective is to evaluate the long-term response of subjects receiving desvenlafaxine succinate sustained release tablets by clinical global evaluation, general well-being and absence of symptoms.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Major Depressive Disorder
Intervention  ICMJE Drug: desvenlafaxine succinate sustained release tablets
25-mg or 50-mg DVS SR tablets taken orally, once daily, at the same time each day. 100 mg dose will be supplied as 2 tablets of 50-mg tablet.
Other Name: DVS-233; Pristiq
Study Arms  ICMJE Experimental: 1
DVS SR
Intervention: Drug: desvenlafaxine succinate sustained release tablets
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: March 31, 2011)
304
Original Estimated Enrollment  ICMJE
 (submitted: January 28, 2009)
339
Actual Study Completion Date  ICMJE March 2011
Actual Primary Completion Date March 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Outpatients who have completed double-blind therapy in short-term study for the indication of major depressive disorder (MDD), including scheduled evaluations, with no major protocol violations and no study events that, in the opinion of the investigator, would preclude the subject's entry into the long-term, open-label study.

Exclusion Criteria:

  • Clinically important abnormalities on baseline (day 56 of the short-term study) physical examination, or any unresolved clinically significant abnormalities on electrocardiogram (ECG), laboratory test results, or vital signs recorded before day 56 in the previous short-term study for the indication of MDD.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 20 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Japan
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00831415
Other Study ID Numbers  ICMJE 3151A1-3350
B2061002
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date November 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP